Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy). Data from the phase III ASCENT-03 study ...

Poor penetrability and nonselective distribution of chemotherapeutic drugs are the main obstacles for chemotherapy for triple-negative breast cancer (TNBC). In our work, we developed a DNA-based drug ...

to breast epithelial cancer, in the former using tissue culture and in the latter laser microdissection of stromal tissue both adjacent and distal to breast invasive ductal cancer (IDC). From ...

The incidence was similar between the left and right breasts, with most patients diagnosed with grade 2 invasive ductal carcinoma, no vascular emboli, a human epidermal growth factor receptor 2 score ...

About 316,950 new cases of invasive breast cancer will be diagnosed in women. About 59,080 new cases of ductal carcinoma in situ (DCIS) will be diagnosed. About 42,170 women will die from breast ...

To investigate the risk of upper urinary tract urothelial carcinoma (UTUC) in patients with non-muscle-invasive bladder cancer (NMIBC), in relation to the primary NMIBC tumour risk categories, ...

In this phase II prospective study that included 101 evaluable patients, 36 of whom had residual disease at surgery, the negative predictive value ... Eligible patients included those with operable ...

“We are excited to discuss our data with the Advisory Committee and broader medical community as we continue our mission to bring innovative solutions to patients suffering from bladder cancer ...

Abbreviations: CDK, cyclin-dependent kinase; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; TNBC, triple-negative breast cancer ... metastatic invasive lobular carcinoma.

The identification of tumour-specific protein–protein interactions remains a challenge for the development of targeted cancer therapies. In this study we describe our approach for the identification ...